Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain
Aída González-Díaz(Instituto de Salud Carlos III), Carmen Ardanuy(Bellvitge University Hospital), Jordi Cámara(Instituto de Salud Carlos III), D. Fontanals(Corporació Sanitària Parc Taulí), María Dolores Quesada(Hospital Universitari Germans Trias i Pujol), Nieves Larrosa(Vall d'Hebron Hospital Universitari), José Yuste(Instituto de Salud Carlos III), María Ercibengoa(Instituto de Salud Carlos III), José María Marimón(Instituto de Salud Carlos III), Emilia Cercenado(Hospital Universitario Lucus Augusti), Meritxell Cubero(Instituto de Salud Carlos III)
Cited by 51
Related Papers
Predictive Factors for Invasive Disease Due to Penicillin-Resistant Streptococcus pneumoniae: A Population-Based Study
|Clinical Infectious Diseases|1994|219
Biofilm Formation Avoids Complement Immunity and Phagocytosis of Streptococcus pneumoniae
|Infection and Immunity|2013|162
<i>Streptococcus pneumoniae</i> Resistance to Complement-Mediated Immunity Is Dependent on the Capsular Serotype
|Infection and Immunity|2009|117
Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
|Clinical Infectious Diseases|2020|113